AbbVie Inc.
ABBVAbbVie Inc., also known as AbbVie, is an American pharmaceutical company headquartered in North Chicago, Illinois. AbbVie produces drugs to treat a wide range of medical issues. The company is ranked sixth on the list of largest biomedical companies by revenue. It is ranked 77th on the Fortune 500 and 108th on the Forbes Global 2000.
Drugs in Pipeline
195
Phase 3 Programs
120
Upcoming Catalysts
22
Next Catalyst
This month
Market Overview
Stock performance and key metrics
23 upcoming, 3 past
Bimatoprost SR Phase 3 Est. Readout
Estimated primary completion for Bimatoprost SR trial (NCT03891446) in Open-Angle Glaucoma. Topline data typically follows completion by weeks to months.
SourceMirvetuximab Soravtansine Phase 2 Est. Readout
Primary completion for Mirvetuximab Soravtansine trial (NCT06365853) in Recurrent Ovarian Cancer
Source21 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How ABBV's past catalysts played out
Ranibizumab (LUCENTIS®)
AMD
Elagolix
Polycystic Ovary Syndrome
ABT-712
Chronic Low Back Pain
Ubrogepant
Migraine
Glecaprevir/Pibrentasvir
Hepatitis C Virus (HCV)
Ubrogepant 100 mg
Migraine
Estradiol/Norethindrone Acetate
Endometriosis
Vedolizumab
Ulcerative Colitis
Obinutuzumab
Chronic Lymphocytic Leukemia (CLL)
Levodopa-carbidopa intestinal gel
Advanced Parkinson's Disease
ABT-493
Chronic Hepatitis C
OnabotulinumtoxinA
Forehead Lines
Topotecan
Small Cell Lung Cancer
Dasabuvir
Chronic Hepatitis C Infection
Bendamustine
Chronic Lymphocytic Leukemia (CLL)
Bortezomib
Relapsed/Refractory Multiple Myeloma
Prednisolone
Takayasu Arteritis (TAK)
Dalbavancin
Methicillin-Resistant Staphylococcus Aureus
Mirvetuximab Soravtansine
Epithelial Ovarian Cancer
Dexamethasone
Relapsed/Refractory Multiple Myeloma
Abatacept
Rheumatoid Arthritis (RA)
Telisotuzumab Adizutecan
Non-Small Cell Lung Cancer
ABT-SLV187
Advanced Parkinson's Disease
AGN-151586
Glabellar Lines
Atogepant
Chronic Migraine
Estradiol /norethindrone acetate (E2/NETA)
Heavy Menstrual Bleeding
Palivizumab
Respiratory Syncytial Virus (RSV)
Levodopa-Carbidopa Intestinal Gel (LCIG)
Advanced Parkinson's Disease
secukinumab
Psoriasis
Best Available Therapy (BAT)
Myelofibrosis (MF)
Aflibercept (EYLEA®)
AMD
Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers)
Irritable Bowel Syndrome With Constipation
ABBV-444
Dry Eye Disease
Telaprevir
Chronic Hepatitis C Infection
Trifluridine/Tipiracil
Metastatic Colorectal Cancer
Azacitidine
Acute Myeloid Leukemia (AML)
Methotrexate
Psoriasis
Upadacitinib (ABT-494)
Ulcerative Colitis (UC)
Armour Thyroid
Hypothyroidism
ABT-874
Plaque Psoriasis
Antidepressant Therapy (ADT)
Major Depressive Disorder
Cyclophosphamide
Triple Negative Breast Cancer
Leuprolide Acetate (LA)
Central Precocious Puberty (CPP)
Carboplatin
High Grade Ovarian Cancer
risankizumab IV
Crohn Disease
Ribavirin (RBV)
Chronic Hepatitis C Virus (HCV) Infection Genotype 1
ABT-450/r/ABT-267, ABT-333
Chronic Hepatitis C Infection
Open-label Adalimumab
Axial Spondyloarthritis
Sofosbuvir
Chronic Hepatitis C
ombitasvir/paritaprevir/ritonavir, dasabuvir
Chronic Hepatitis C Virus (HCV Infection Genotype 1)
Cisplatin
Non-squamous Non-small Cell Lung Cancer
Topiramate
Migraine
Livmoniplimab
Hepatocellular Carcinoma
Budigalimab
Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma
Cariprazine Flexible Dose
Schizophrenia
ABT-450/r/ABT-267
Hepatitis C Virus Infection
AGN-190584
Presbyopia
Carfilzomib
Multiple Myeloma
Elotuzumab
Multiple Myeloma
Glecaprevir/Pibrentasvir (GLE/PIB)
Hepatitis C Virus (HCV)
Topical corticosteroids (TCS)
Atopic Dermatitis
Pemetrexed
Non-Small Cell Lung Cancer
Paricalcitol
Chronic Kidney Disease Stage 3 and 4
Surabgene Lomparvovec
Diabetic Retinopathy
Ruxolitinib
Myelofibrosis (MF)
Prednisone
Uveitis
OBV/PTV/r
Chronic Hepatitis C Virus
ABT-493/ABT-530
Hepatitis C Virus Infection
Botulinum Toxin Type A
Masseter Muscle Prominence
Linaclotide
Functional Constipation (FC)
ribavirin
Chronic Hepatitis C Infection
Cytarabine
Acute Myelogenous Leukemia
Tavapadon
Parkinson Disease
ABT-493 coformulated with ABT-530
Hepatitis C Virus Infection
sofosbuvir (SOF)
Chronic Hepatitis C Virus
Etentamig
Multiple Myeloma
Standard of Care
Non-Squamous Non-Small Cell Lung Cancer
2 DAA
HCV
Glecaprevir/Pibrentasvir Adult Formulation
Hepatitis C Virus (HCV)
Risankizumab SC
Crohn's Disease
Upadacitinib
Ulcerative Colitis (UC)
ombitasvir/paritaprevir/ritonavir and dasabuvir
Hepatitis C Virus (HCV)
Veliparib
Metastatic Breast Cancer
adalimumab
Pyoderma Gangrenosum
Risankizumab
Crohn's Disease (CD)
Rovalpituzumab tesirine
Small Cell Lung Cancer
ombitasvir/paritaprevir/ritonavir
Hepatitis C Infection
Cariprazine
Depression
Paclitaxel
Metastatic Breast Cancer
ABBV-951
Parkinson's Disease (PD)
etanercept
Moderate to Severe Plaque Psoriasis
Acalabrutinib
Chronic Lymphocytic Leukemia
BOTOX
Masseter Muscle Prominence
Corticosteroid (CS)
Giant Cell Arteritis (GCA)
Venetoclax
Acute Myeloid Leukemia (AML)
Pegylated Interferon a-2a (PegINF)
Chronic Hepatitis C Infection
Navitoclax
Myelofibrosis (MF)
ABT-493, ABT-530
Chronic Hepatitis C
Tocilizumab
Juvenile Idiopathic Arthritis
Fumaderm
Psoriasis
Fluvoxamine maleate
Obsessive Compulsive Disorder
Combined Oral Contraceptive
Endometriosis
Ustekinumab
Psoriasis
Atogepant 60 mg
Chronic Migraine
ABT-530
Chronic Hepatitis C
Temozolomide
Glioblastoma
LUMIGAN
Open-Angle Glaucoma
Pomalidomide
Multiple Myeloma
maxacalcitol
Secondary Hyperparathyroidism
Optimized antiparkinsonian treatment
Parkinson's Disease (PD)
Lutikizumab
Hidradenitis Suppurativa
Bimatoprost (SR)
Open-Angle Glaucoma
Telisotuzumab vedotin
Non-small Cell Lung Cancer
Bimatoprost SR
Open-Angle Glaucoma
Docetaxel
Non Small Cell Lung Cancer
ABT-333
Chronic Hepatitis C Infection
Upadacitinib 15mg Dose
Atopic Dermatitis
Dupilumab
Atopic Dermatitis
Optimized Medical Treatment
Advanced Parkinson's Disease
Surabgene Lomparvovec (ABBV-RGX-314)
Neovascular Age-related Macular Degeneration
Emraclidine
Schizophrenia
ABBV-8E12
Alzheimer's Disease
ABT-450
Hepatitis C Virus
ABBV-382
Crohn's Disease
ABT-981
Erosive Hand Osteoarthritis
Ranibizumab
Neovascular Age-Related Macular Degeneration (nAMD)
ABBV-142
Idiopathic Pulmonary Fibrosis
hydrocodone/acetaminophen extended release
Chronic Low Back Pain
atomoxetine
Attention-Deficit/Hyperactivity Disorder
ABT-869
Advanced Hepatocellular Carcinoma
ABBV-6628
Geographic Atrophy
ABT-450/ritonavir (r)
Chronic Hepatitis C
Depatuxizumab mafodotin
Glioblastoma
Gemcitabine
Urothelial Carcinoma
ABBV-453
Multiple Myeloma
Ravagalimab 600 mg
Ulcerative Colitis (UC)
Leuprorelin Acetate Depot
Endometriosis
ABBV-932
Generalized Anxiety Disorder (GAD)
ABT-414
Malignant Glioma
Ombitasvir/ABT-450/Ritonavir
Chronic Hepatitis C
ABT-126
Schizophrenia
Topical Steroid
Diabetic Retinopathy (DR)
Icalcaprant
Major Depressive Disorder
Ibrutinib
Mantle Cell Lymphoma (MCL)
Emraclidine 15 mg
Schizophrenia
ABT-267
Chronic Hepatitis C
ABBV-3067
Cystic Fibrosis
ABT-199 (Main Cohort)
Chronic Lymphocytic Leukemia
CVL-871 1.0 mg
Apathy in Dementia
IMGN632
Acute Myeloid Leukemia
ABBV-916
Alzheimer's Disease (AD)
Modified FOLFIRI
Untreated Metastatic Colorectal Cancer
donepezil
Alzheimer's Disease
Darigabat
Panic Disorder
AGN-151597
Advanced Retinitis Pigmentosa
Etoposide
Small Cell Lung Cancer
ABBV-3373
Rheumatoid Arthritis (RA)
Eluxadoline
Irritable Bowel Syndrome
Pneumococcal 13-valent conjugate vaccine (PCV-13)
Rheumatoid Arthritis
AGN-193408 SR
Open-angle Glaucoma
MEDI0618
Migraine
ABT-719
Acute Kidney Injury
ABBV-706
Small Cell Lung Cancer
Subcutaneous depot medroxyprogesterone acetate (DMPA-SC)
Endometriosis
ABT-199
Acute Myelogenous Leukemia
ABT-072
Hepatitis C Virus Infection
Ritonavir
Chronic Hepatitis C Infection
ABT-894
Diabetic Neuropathic Pain
ABT-494
Crohn's Disease
ABT-263
Chronic Lymphoid Leukemia
ABBV-400
Unresectable Metastatic Colorectal Cancer
Ravagalimab
Rheumatoid Arthritis
ABT-089
Attention Deficit Hyperactivity Disorder
Elsubrutinib
Systemic Lupus Erythematosus (SLE)
elezanumab
Multiple Sclerosis (MS)
CVL-865
Seizures
AGN-151607
Post-Operative Atrial Fibrillation
ABT-122
Rheumatoid Arthritis
azacitadine
Non-Hodgkin Lymphoma (NHL)
ABBV-552
Alzheimer's Disease (AD)
ABBV-668
Ulcerative Colitis
Daratumumab
Multiple Myeloma
Lubricating Eye Drops
Recurrent Ovarian Cancer
CVL-231 30 mg
Schizophrenia
Risankizumab 600 mg IV
Crohn Disease
AGN-151607-DP
Ventral Hernia
TNB-383B
Multiple Myeloma
IMGN151
Gynecologic Cancers
Emraclidine 10 mg
Schizophrenia
Lenvatinib
Hepatocellular Carcinoma
0.5 mg estradiol / 0.1 mg norethindrone acetate
Heavy Uterine Bleeding
Panitumumab
Metastatic Colorectal Cancer
ABBV-383 (Etentamig)
Immunoglobulin Light Chain (AL) Amyloidosis
Atrasentan
Nephropathy
AGN-242428
Dry Eye Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Ranibizumab (LUCENTIS®) | Phase 3 | AMD | - | - |
Elagolix | Phase 3 | Polycystic Ovary Syndrome | - | - |
ABT-712 | Phase 3 | Chronic Low Back Pain | - | - |
Ubrogepant | Phase 3 | Migraine | - | - |
Glecaprevir/Pibrentasvir | Phase 3 | Hepatitis C Virus (HCV) | - | - |
Ubrogepant 100 mg | Phase 3 | Migraine | - | - |
Estradiol/Norethindrone Acetate | Phase 3 | Endometriosis | - | - |
Vedolizumab | Phase 3 | Ulcerative Colitis | - | - |
Obinutuzumab | Phase 3 | Chronic Lymphocytic Leukemia (CLL) | - | - |
Levodopa-carbidopa intestinal gel | Phase 3 | Advanced Parkinson's Disease | - | - |
ABT-493 | Phase 3 | Chronic Hepatitis C | - | - |
OnabotulinumtoxinA | Phase 3 | Forehead Lines | - | - |
Topotecan | Phase 3 | Small Cell Lung Cancer | - | - |
Dasabuvir | Phase 3 | Chronic Hepatitis C Infection | - | - |
Bendamustine | Phase 3 | Chronic Lymphocytic Leukemia (CLL) | - | - |
Bortezomib | Phase 3 | Relapsed/Refractory Multiple Myeloma | - | - |
Prednisolone | Phase 3 | Takayasu Arteritis (TAK) | - | - |
Dalbavancin | Phase 3 | Methicillin-Resistant Staphylococcus Aureus | - | - |
Mirvetuximab Soravtansine | Phase 3 | Epithelial Ovarian Cancer | - | - |
Dexamethasone | Phase 3 | Relapsed/Refractory Multiple Myeloma | - | - |
Abatacept | Phase 3 | Rheumatoid Arthritis (RA) | - | - |
Telisotuzumab Adizutecan | Phase 3 | Non-Small Cell Lung Cancer | - | - |
ABT-SLV187 | Phase 3 | Advanced Parkinson's Disease | - | - |
AGN-151586 | Phase 3 | Glabellar Lines | - | - |
Atogepant | Phase 3 | Chronic Migraine | - | - |
Estradiol /norethindrone acetate (E2/NETA) | Phase 3 | Heavy Menstrual Bleeding | - | - |
Palivizumab | Phase 3 | Respiratory Syncytial Virus (RSV) | - | - |
Levodopa-Carbidopa Intestinal Gel (LCIG) | Phase 3 | Advanced Parkinson's Disease | - | - |
secukinumab | Phase 3 | Psoriasis | - | - |
Best Available Therapy (BAT) | Phase 3 | Myelofibrosis (MF) | - | - |
Aflibercept (EYLEA®) | Phase 3 | AMD | - | - |
Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers) | Phase 3 | Irritable Bowel Syndrome With Constipation | - | - |
ABBV-444 | Phase 3 | Dry Eye Disease | - | - |
Telaprevir | Phase 3 | Chronic Hepatitis C Infection | - | - |
Trifluridine/Tipiracil | Phase 3 | Metastatic Colorectal Cancer | - | - |
Azacitidine | Phase 3 | Acute Myeloid Leukemia (AML) | - | - |
Methotrexate | Phase 3 | Psoriasis | - | - |
Upadacitinib (ABT-494) | Phase 3 | Ulcerative Colitis (UC) | - | - |
Armour Thyroid | Phase 3 | Hypothyroidism | - | - |
ABT-874 | Phase 3 | Plaque Psoriasis | - | - |
Antidepressant Therapy (ADT) | Phase 3 | Major Depressive Disorder | - | - |
Cyclophosphamide | Phase 3 | Triple Negative Breast Cancer | - | - |
Leuprolide Acetate (LA) | Phase 3 | Central Precocious Puberty (CPP) | - | - |
Carboplatin | Phase 3 | High Grade Ovarian Cancer | - | - |
risankizumab IV | Phase 3 | Crohn Disease | - | - |
Ribavirin (RBV) | Phase 3 | Chronic Hepatitis C Virus (HCV) Infection Genotype 1 | - | - |
ABT-450/r/ABT-267, ABT-333 | Phase 3 | Chronic Hepatitis C Infection | - | - |
Open-label Adalimumab | Phase 3 | Axial Spondyloarthritis | - | - |
Sofosbuvir | Phase 3 | Chronic Hepatitis C | - | - |
ombitasvir/paritaprevir/ritonavir, dasabuvir | Phase 3 | Chronic Hepatitis C Virus (HCV Infection Genotype 1) | - | - |
Cisplatin | Phase 3 | Non-squamous Non-small Cell Lung Cancer | - | - |
Topiramate | Phase 3 | Migraine | - | - |
Livmoniplimab | Phase 3 | Hepatocellular Carcinoma | - | - |
Budigalimab | Phase 3 | Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma | - | - |
Cariprazine Flexible Dose | Phase 3 | Schizophrenia | - | - |
ABT-450/r/ABT-267 | Phase 3 | Hepatitis C Virus Infection | - | - |
AGN-190584 | Phase 3 | Presbyopia | - | - |
Carfilzomib | Phase 3 | Multiple Myeloma | - | - |
Elotuzumab | Phase 3 | Multiple Myeloma | - | - |
Glecaprevir/Pibrentasvir (GLE/PIB) | Phase 3 | Hepatitis C Virus (HCV) | - | - |
Topical corticosteroids (TCS) | Phase 3 | Atopic Dermatitis | - | - |
Pemetrexed | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Paricalcitol | Phase 3 | Chronic Kidney Disease Stage 3 and 4 | - | - |
Surabgene Lomparvovec | Phase 3 | Diabetic Retinopathy | - | - |
Ruxolitinib | Phase 3 | Myelofibrosis (MF) | - | - |
Prednisone | Phase 3 | Uveitis | - | - |
OBV/PTV/r | Phase 3 | Chronic Hepatitis C Virus | - | - |
ABT-493/ABT-530 | Phase 3 | Hepatitis C Virus Infection | - | - |
Botulinum Toxin Type A | Phase 3 | Masseter Muscle Prominence | - | - |
Linaclotide | Phase 3 | Functional Constipation (FC) | - | - |
ribavirin | Phase 3 | Chronic Hepatitis C Infection | - | - |
Cytarabine | Phase 3 | Acute Myelogenous Leukemia | - | - |
Tavapadon | Phase 3 | Parkinson Disease | - | - |
ABT-493 coformulated with ABT-530 | Phase 3 | Hepatitis C Virus Infection | - | - |
sofosbuvir (SOF) | Phase 3 | Chronic Hepatitis C Virus | - | - |
Etentamig | Phase 3 | Multiple Myeloma | - | - |
Standard of Care | Phase 3 | Non-Squamous Non-Small Cell Lung Cancer | - | - |
2 DAA | Phase 3 | HCV | - | - |
Glecaprevir/Pibrentasvir Adult Formulation | Phase 3 | Hepatitis C Virus (HCV) | - | - |
Risankizumab SC | Phase 3 | Crohn's Disease | - | - |
Upadacitinib | Phase 3 | Ulcerative Colitis (UC) | - | - |
ombitasvir/paritaprevir/ritonavir and dasabuvir | Phase 3 | Hepatitis C Virus (HCV) | - | - |
Veliparib | Phase 3 | Metastatic Breast Cancer | - | - |
adalimumab | Phase 3 | Pyoderma Gangrenosum | - | - |
Risankizumab | Phase 3 | Crohn's Disease (CD) | - | - |
Rovalpituzumab tesirine | Phase 3 | Small Cell Lung Cancer | - | - |
ombitasvir/paritaprevir/ritonavir | Phase 3 | Hepatitis C Infection | - | - |
Cariprazine | Phase 3 | Depression | - | - |
Paclitaxel | Phase 3 | Metastatic Breast Cancer | - | - |
ABBV-951 | Phase 3 | Parkinson's Disease (PD) | - | - |
etanercept | Phase 3 | Moderate to Severe Plaque Psoriasis | - | - |
Acalabrutinib | Phase 3 | Chronic Lymphocytic Leukemia | - | - |
BOTOX | Phase 3 | Masseter Muscle Prominence | - | - |
Corticosteroid (CS) | Phase 3 | Giant Cell Arteritis (GCA) | - | - |
Venetoclax | Phase 3 | Acute Myeloid Leukemia (AML) | - | - |
Pegylated Interferon a-2a (PegINF) | Phase 3 | Chronic Hepatitis C Infection | - | - |
Navitoclax | Phase 3 | Myelofibrosis (MF) | - | - |
ABT-493, ABT-530 | Phase 3 | Chronic Hepatitis C | - | - |
Tocilizumab | Phase 3 | Juvenile Idiopathic Arthritis | - | - |
Fumaderm | Phase 3 | Psoriasis | - | - |
Fluvoxamine maleate | Phase 3 | Obsessive Compulsive Disorder | - | - |
Combined Oral Contraceptive | Phase 3 | Endometriosis | - | - |
Ustekinumab | Phase 3 | Psoriasis | - | - |
Atogepant 60 mg | Phase 3 | Chronic Migraine | - | - |
ABT-530 | Phase 3 | Chronic Hepatitis C | - | - |
Temozolomide | Phase 3 | Glioblastoma | - | - |
LUMIGAN | Phase 3 | Open-Angle Glaucoma | - | - |
Pomalidomide | Phase 3 | Multiple Myeloma | - | - |
maxacalcitol | Phase 3 | Secondary Hyperparathyroidism | - | - |
Optimized antiparkinsonian treatment | Phase 3 | Parkinson's Disease (PD) | - | - |
Lutikizumab | Phase 3 | Hidradenitis Suppurativa | - | - |
Bimatoprost (SR) | Phase 3 | Open-Angle Glaucoma | - | - |
Telisotuzumab vedotin | Phase 3 | Non-small Cell Lung Cancer | - | - |
Bimatoprost SR | Phase 3 | Open-Angle Glaucoma | - | - |
Docetaxel | Phase 3 | Non Small Cell Lung Cancer | - | - |
ABT-333 | Phase 3 | Chronic Hepatitis C Infection | - | - |
Upadacitinib 15mg Dose | Phase 3 | Atopic Dermatitis | - | - |
Dupilumab | Phase 3 | Atopic Dermatitis | - | - |
Optimized Medical Treatment | Phase 3 | Advanced Parkinson's Disease | - | - |
Surabgene Lomparvovec (ABBV-RGX-314) | Phase 3 | Neovascular Age-related Macular Degeneration | - | - |
Emraclidine | Phase 2 | Schizophrenia | - | - |
ABBV-8E12 | Phase 2 | Alzheimer's Disease | - | - |
ABT-450 | Phase 2 | Hepatitis C Virus | - | - |
ABBV-382 | Phase 2 | Crohn's Disease | - | - |
ABT-981 | Phase 2 | Erosive Hand Osteoarthritis | - | - |
Ranibizumab | Phase 2 | Neovascular Age-Related Macular Degeneration (nAMD) | - | - |
ABBV-142 | Phase 2 | Idiopathic Pulmonary Fibrosis | - | - |
hydrocodone/acetaminophen extended release | Phase 2 | Chronic Low Back Pain | - | - |
atomoxetine | Phase 2 | Attention-Deficit/Hyperactivity Disorder | - | - |
ABT-869 | Phase 2 | Advanced Hepatocellular Carcinoma | - | - |
ABBV-6628 | Phase 2 | Geographic Atrophy | - | - |
ABT-450/ritonavir (r) | Phase 2 | Chronic Hepatitis C | - | - |
Depatuxizumab mafodotin | Phase 2 | Glioblastoma | - | - |
Gemcitabine | Phase 2 | Urothelial Carcinoma | - | - |
ABBV-453 | Phase 2 | Multiple Myeloma | - | - |
Ravagalimab 600 mg | Phase 2 | Ulcerative Colitis (UC) | - | - |
Leuprorelin Acetate Depot | Phase 2 | Endometriosis | - | - |
ABBV-932 | Phase 2 | Generalized Anxiety Disorder (GAD) | - | - |
ABT-414 | Phase 2 | Malignant Glioma | - | - |
Ombitasvir/ABT-450/Ritonavir | Phase 2 | Chronic Hepatitis C | - | - |
ABT-126 | Phase 2 | Schizophrenia | - | - |
Topical Steroid | Phase 2 | Diabetic Retinopathy (DR) | - | - |
Icalcaprant | Phase 2 | Major Depressive Disorder | - | - |
Ibrutinib | Phase 2 | Mantle Cell Lymphoma (MCL) | - | - |
Emraclidine 15 mg | Phase 2 | Schizophrenia | - | - |
ABT-267 | Phase 2 | Chronic Hepatitis C | - | - |
ABBV-3067 | Phase 2 | Cystic Fibrosis | - | - |
ABT-199 (Main Cohort) | Phase 2 | Chronic Lymphocytic Leukemia | - | - |
CVL-871 1.0 mg | Phase 2 | Apathy in Dementia | - | - |
IMGN632 | Phase 2 | Acute Myeloid Leukemia | - | - |
ABBV-916 | Phase 2 | Alzheimer's Disease (AD) | - | - |
Modified FOLFIRI | Phase 2 | Untreated Metastatic Colorectal Cancer | - | - |
donepezil | Phase 2 | Alzheimer's Disease | - | - |
Darigabat | Phase 2 | Panic Disorder | - | - |
AGN-151597 | Phase 2 | Advanced Retinitis Pigmentosa | - | - |
Etoposide | Phase 2 | Small Cell Lung Cancer | - | - |
ABBV-3373 | Phase 2 | Rheumatoid Arthritis (RA) | - | - |
Eluxadoline | Phase 2 | Irritable Bowel Syndrome | - | - |
Pneumococcal 13-valent conjugate vaccine (PCV-13) | Phase 2 | Rheumatoid Arthritis | - | - |
AGN-193408 SR | Phase 2 | Open-angle Glaucoma | - | - |
MEDI0618 | Phase 2 | Migraine | - | - |
ABT-719 | Phase 2 | Acute Kidney Injury | - | - |
ABBV-706 | Phase 2 | Small Cell Lung Cancer | - | - |
Subcutaneous depot medroxyprogesterone acetate (DMPA-SC) | Phase 2 | Endometriosis | - | - |
ABT-199 | Phase 2 | Acute Myelogenous Leukemia | - | - |
ABT-072 | Phase 2 | Hepatitis C Virus Infection | - | - |
Ritonavir | Phase 2 | Chronic Hepatitis C Infection | - | - |
ABT-894 | Phase 2 | Diabetic Neuropathic Pain | - | - |
ABT-494 | Phase 2 | Crohn's Disease | - | - |
ABT-263 | Phase 2 | Chronic Lymphoid Leukemia | - | - |
ABBV-400 | Phase 2 | Unresectable Metastatic Colorectal Cancer | - | - |
Ravagalimab | Phase 2 | Rheumatoid Arthritis | - | - |
ABT-089 | Phase 2 | Attention Deficit Hyperactivity Disorder | - | - |
Elsubrutinib | Phase 2 | Systemic Lupus Erythematosus (SLE) | - | - |
elezanumab | Phase 2 | Multiple Sclerosis (MS) | - | - |
CVL-865 | Phase 2 | Seizures | - | - |
AGN-151607 | Phase 2 | Post-Operative Atrial Fibrillation | - | - |
ABT-122 | Phase 2 | Rheumatoid Arthritis | - | - |
azacitadine | Phase 2 | Non-Hodgkin Lymphoma (NHL) | - | - |
ABBV-552 | Phase 2 | Alzheimer's Disease (AD) | - | - |
ABBV-668 | Phase 2 | Ulcerative Colitis | - | - |
Daratumumab | Phase 2 | Multiple Myeloma | - | - |
Lubricating Eye Drops | Phase 2 | Recurrent Ovarian Cancer | - | - |
CVL-231 30 mg | Phase 2 | Schizophrenia | - | - |
Risankizumab 600 mg IV | Phase 2 | Crohn Disease | - | - |
AGN-151607-DP | Phase 2 | Ventral Hernia | - | - |
TNB-383B | Phase 2 | Multiple Myeloma | - | - |
IMGN151 | Phase 2 | Gynecologic Cancers | - | - |
Emraclidine 10 mg | Phase 2 | Schizophrenia | - | - |
Lenvatinib | Phase 2 | Hepatocellular Carcinoma | - | - |
0.5 mg estradiol / 0.1 mg norethindrone acetate | Phase 2 | Heavy Uterine Bleeding | - | - |
Panitumumab | Phase 2 | Metastatic Colorectal Cancer | - | - |
ABBV-383 (Etentamig) | Phase 2 | Immunoglobulin Light Chain (AL) Amyloidosis | - | - |
Atrasentan | Phase 2 | Nephropathy | - | - |
AGN-242428 | Phase 2 | Dry Eye Disease | - | - |
Dry Eye Disease
1 drug in this indication
Alzheimer's Disease
1 drug in this indication
Open-Angle Glaucoma
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in AbbVie Inc.'s drug pipeline?→
CatalystAlert tracks 195 drug candidates in AbbVie Inc.'s (ABBV) pipeline across Phase 3, Phase 2. Its lead program is Ranibizumab (LUCENTIS®) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is AbbVie Inc.'s next FDA catalyst?→
AbbVie Inc.'s (ABBV) next tracked catalyst is a Phase 3 expected July 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ABBV biotech catalysts?→
Add ABBV to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow AbbVie Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.